WallStSmart
GEHC

GE HealthCare Technologies Inc.

NASDAQ: GEHC · HEALTHCARE · MEDICAL DEVICES

$59.49
-13.16% today

Updated 2026-04-29

Market cap
$27.06B
P/E ratio
14.27
P/S ratio
1.31x
EPS (TTM)
$4.17
Dividend yield
—
52W range
$59 – $90
Volume
3.9M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

GE HealthCare Technologies Inc. (GEHC) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$59.49
Consensus
$89.75
+50.88%
2030 Target
$703.50
+1082.65%
DCF
$137.94
+42.58% MoS
12 analysts:
3 Buy4 Hold1 Sell

Management guidance

No specific CEO revenue targets found in available data. Company has reaffirmed 2026 growth guidance and teased 2027 imaging revenue boost. Management has not disclosed specific revenue dollar targets through 2030.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$1,167.81
$26.7B Rev × 20x P/S
Base case (2030)
$703.50
$26.7B Rev × 12x P/S
Bear case (2030)
$471.35
$26.7B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2028 (E)2029 (E)2030 (E)
Revenue$19.6B$19.7B$20.6B$22.1B$24.2B$25.4B$26.7B
Revenue growth—0.6%4.8%7.1%4.9%5.0%5.1%
EPS$3.94$4.61$4.43$5.17$6.15$6.68$7.25
P/S ratio———12.0x12.0x12.0x12.0x
Implied price———$583.91$633.15$668.33$703.50

Catalysts & risks

Growth catalysts
+ FDA clearance for Photonova Spectra photon-counting CT system driving next-generation imaging revenue
+ Completed Intelerad acquisition accelerating cloud-first digital health solutions and software revenue
+ UCSF 10-year alliance advancing precision imaging and AI-enabled diagnostics across healthcare systems
+ Multiple FDA clearances for SIGNA MRI portfolio and View diagnostic viewer enhancing competitive positioning
+ Strong backlog demand signaling robust order intake and near-term revenue conversion
Key risks
- Potential 100% tariffs on imported medical devices creating supply chain and margin pressures
- China policy risks and geopolitical uncertainties affecting manufacturing and international expansion
- Healthcare policy shifts and hospital capex spending volatility impacting device demand
- Free cash flow pressure despite revenue growth limiting investment and shareholder returns
- Recent stock underperformance (-21.58% from 52-week high) despite operational improvements

Methodology

GE HealthCare Technologies Inc.'s forward estimates are derived from AI-powered research synthesis combining analyst consensus from 12 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.